Evidence map›Paper›PMID 38347998›Full record

ArticleCureus2024

A Clinical Suspicion of Quetiapine-Induced Psychosis: A Case Report and Literature Review.

Michael J Valentine, Ankur Kayastha, Takara R Newsome-Cuby, Anh Thu N Nguyen, Riley G Fisher, Hanh M Pham, Saif A Meimon, Alexander Phu, Connor A Parry, Joshua J Nelson and 2 more

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Michael J ValentineCollege of Osteopathic Medicine, Kansas City University, Kansas City, USA.
Ankur KayasthaCollege of Osteopathic Medicine, Kansas City University, Kansas City, USA.
Takara R Newsome-CubyCollege of Osteopathic Medicine, Kansas City University, Kansas City, USA.
Anh Thu N NguyenCollege of Osteopathic Medicine, Kansas City University, Kansas City, USA.
Riley G FisherCollege of Life Sciences, Brigham Young University, Provo, USA.
Hanh M PhamCollege of Osteopathic Medicine, Kansas City University, Kansas City, USA.
Saif A MeimonCollege of Osteopathic Medicine, Kansas City University, Kansas City, USA.
Alexander PhuCollege of Osteopathic Medicine, Kansas City University, Kansas City, USA.
Connor A ParryCollege of Osteopathic Medicine, Kansas City University, Kansas City, USA.
Joshua J NelsonCollege of Osteopathic Medicine, Kansas City University, Kansas City, USA.
Ethan C HayesCollege of Osteopathic Medicine, Kansas City University, Joplin, USA.
Sunita MuranjanPsychiatry, Integrated Psychiatric Consultants, Kansas City, USA.
Kansas City University · USClinical Research Consultants (United States) · USNebraska Medical Center · USUniversity of Nebraska Medical Center · USBrigham Young University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Quetiapine, a pharmacological agent within the class of atypical antipsychotics, is characterized by its efficacy in mood stabilization and its role in the modulation of serotonergic and dopaminergic pathways. Its therapeutic utility is broad, encompassing the management of acute psychotic episodes, schizophrenia, bipolar disorder, and treatment-resistant depressive states. Quetiapine's effectiveness extends to depressive disorders that do not exhibit classic psychotic features, with a side effect profile that is less burdensome than many alternative psychotropic medications. Its versatility in addressing a range of psychiatric conditions is useful in the psychopharmacological management of mood and thought disorders. However, like all drugs, quetiapine may have different effects relative to the individual. It is imperative to approach the administration of quetiapine carefully, ensuring any adverse effects are ameliorated for beneficial therapeutic outcomes. In this case report, we present a psychosis-naive 42-year-old male who developed psychotic symptoms after beginning a quetiapine regimen in order to manage major depressive disorder with suicidal ideation. Clinical suspicion of quetiapine-induced psychosis was a diagnosis considered due to symptom remission secondary to ziprasidone in the place of quetiapine. The determination of a suspected adverse drug reaction can utilize the Naranjo scale to demonstrate the likelihood of an adverse drug reaction. This patient scored a three on the Naranjo scale, indicating a possible adverse effect from quetiapine. Other potential etiologies of psychosis include medication-induced psychosis, major depressive disorder exacerbation, cocaine use/withdrawal, and brief psychotic disorder. Quetiapine-induced psychosis has not been described in the current literature, and therefore, this case report is solely based on clinical evaluation and is intended for educational purposes due to possible confounding factors and etiologies.

Indexed as

brief psychotic disorderdrug-induced psychosishallucinationsnaranjo scalenaranjo scorepsychosisquetiapineseroquelsubstance-induced psychosisziprasidone

Identifiers

PMID38347998
PMCPMC10859674
OpenAlexW4390824689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.